ClinicalTrials.gg
WithdrawnNCT00754689Updated May 17, 2016

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

A Phase 3 interventional study of Rimonabant and Metformin in Diabetes Mellitus, Type 2, sponsored by Sanofi. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-17.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Company decision taken in light of demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing rimonabant in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rimonabant · Diabetes Mellitus, Type 2.

Enrollment
11th of 11
0 · median 358
Started
2008
with 1 other
Phase 3
10 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
10 of 11
Sanofi

Among the 11 studies testing rimonabant in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 11 studies testing rimonabant in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing rimonabant in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The primary objective of the study is to demonstrate superiority of rimonabant/metformin combinations in Glycosylated Hemoglobin 1c (A1C) reduction over the corresponding single agent metformin and over rimonabant alone in patients with type 2 diabetes mellitus at 9 months.

The secondary objective is to investigate the effects of rimonabant/metformin combinations for reducing fasted plasma glucose, body weight and triglycerides, and raising High Density Lipoprotein Cholesterol (HDL-C) in comparison with metformin at 9 months.

Another objective is to evaluate the safety of rimonabant in combination with metformin over a period of up to 52 weeks.

Read the detailed description

The duration per patient is up to 65 weeks: 1 - 2 weeks screening, up to 52 weeks double blind treatment, and 75 days post last dose. This study will end for all patients when the last patient has been treated for at least 9 months.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Rimonabant/metformin combination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of type 2 diabetes mellitus diagnosed prior to the screening visit 1 (ADA criteria)
  • Patients must not have used any oral or injectable glucose lowering medication at least 12 weeks prior to the screening visit to establish a stable, comparable baseline assessment in all patients
  • A1C ≥7.0 % and ≤10.0 %
  • Fasted plasma glucose at screening visit ≤260 mg/dL (14.44 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • Treatment with any anti-diabetic oral agent, or injectable antidiabetic agent within 12 weeks prior to screening visit
  • In the 3 months prior to the screening visit, use of any anti-obesity agent or drugs for weight loss, or administration of systemic for more than 7 days
  • Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders
  • Presence or history of cancer within the past five years
  • Pregnant or breast-feeding women, or women of not protected by effective method of

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Metformin 500mg twice daily (bid) + placebo

    Drug: Metformin · Drug: placebo

  • Active comparator
    Arm 2

    Metformin 1000mg bid + placebo

    Drug: Metformin · Drug: placebo

  • Active comparator
    Arm 3

    Rimonabant 20mg once daily (od) + placebo

    Drug: Rimonabant · Drug: placebo

  • Experimental
    Arm 4

    Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid

    Drug: Rimonabant · Drug: Metformin

  • Experimental
    Arm 5

    Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid

    Drug: Rimonabant · Drug: Metformin

Interventions

  • Tablet, oral administration

    Also known as: SR141716, Acomplia

  • Tablet, oral administration

  • Drugplacebo

    Tablet, oral administration

06

What researchers measure

Primary outcomes

  1. Change from baseline in A1C

    Time frame: at 9 months

Secondary outcomes

  1. Change from baseline in fasting plasma glucose

    Time frame: at 9 months

  2. Change from baseline in body weight

    Time frame: at 9 months

  3. Percent change from baseline in triglycerides

    Time frame: at 9 months

  4. Percent change from baseline in HDL-C

    Time frame: at 9 months

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2008
First posted
Sep 18, 2008
Start
Sep 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Last update
May 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00754689
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 18, 2008
Start date
Sep 2008
Primary completion
Nov 2008
Completion
Nov 2008
Last update
May 17, 2016

Study contacts

ICD CSD
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rimonabant · Metformin

Start the discussion